The state of Alabama currently has 38 active clinical trials seeking participants for Lymphoma research studies. These trials are conducted in various cities, including Birmingham, Mobile, Huntsville and Anniston.
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
NCT04981795
Recruiting
The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: Alabama Oncology, Birmingham, Alabama +1 locations
Conditions: Diffuse Large B-cell Lymphoma
Register for Updates
Study of Tazemetostat in Lymphoid Malignancies
NCT05983965
Recruiting
Tazemetostat is an oral EZH2 inhibitor which has been FDA approved for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment option. We propose a study to evaluate the safety of tazemetostat in relapsed / refractory peripheral T-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/05/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: T-cell Lymphoma
Register for Updates